1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Amyloid Beta Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Amyloid Beta Therapeutics Market, by Therapeutic Type
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast
8.1.2. Small Molecule Therapies
8.1.2.1. Market Revenue and Forecast
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast
8.1.4. Combination Therapies
8.1.4.1. Market Revenue and Forecast
9.1. Amyloid Beta Therapeutics Market, by Indication
9.1.1. Alzheimer’s Disease
9.1.1.1. Market Revenue and Forecast
9.1.2. Mild Cognitive Impairment (MCI)
9.1.2.1. Market Revenue and Forecast
9.1.3. Early-stage Alzheimer’s
9.1.3.1. Market Revenue and Forecast
9.1.4. Other Neurodegenerative Disorders
9.1.4.1. Market Revenue and Forecast
10.1. Amyloid Beta Therapeutics Market, by Mechanism of Action
10.1.1. Amyloid Plaque Clearance
10.1.1.1. Market Revenue and Forecast
10.1.2. Amyloid Production Inhibition
10.1.2.1. Market Revenue and Forecast
10.1.3. Neuroinflammation Reduction
10.1.3.1. Market Revenue and Forecast
10.1.4. Synaptic Protection
10.1.4.1. Market Revenue and Forecast
10.1.5. Neuroprotection Enhancement
10.1.5.1. Market Revenue and Forecast
11.1. Amyloid Beta Therapeutics Market, by Route of Administration
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast
11.1.2. Oral
11.1.2.1. Market Revenue and Forecast
11.1.3. Subcutaneous
11.1.3.1. Market Revenue and Forecast
12.1. Amyloid Beta Therapeutics Market, by End-use
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Neurology Clinics
12.1.2.1. Market Revenue and Forecast
12.1.3. Academic & Research Institutes
12.1.3.1. Market Revenue and Forecast
12.1.4. Pharmaceutical & Biotechnology Companies
12.1.4.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapeutic Type
13.1.2. Market Revenue and Forecast, by Indication
13.1.3. Market Revenue and Forecast, by Mechanism of Action
13.1.4. Market Revenue and Forecast, by Route of Administration
13.1.5. Market Revenue and Forecast, by End-use
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapeutic Type
13.1.6.2. Market Revenue and Forecast, by Indication
13.1.6.3. Market Revenue and Forecast, by Mechanism of Action
13.1.6.4. Market Revenue and Forecast, by Route of Administration
13.1.6.5. Market Revenue and Forecast, by End-use
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapeutic Type
13.1.7.2. Market Revenue and Forecast, by Indication
13.1.7.3. Market Revenue and Forecast, by Mechanism of Action
13.1.7.4. Market Revenue and Forecast, by Route of Administration
13.1.7.5. Market Revenue and Forecast, by End-use
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapeutic Type
13.2.2. Market Revenue and Forecast, by Indication
13.2.3. Market Revenue and Forecast, by Mechanism of Action
13.2.4. Market Revenue and Forecast, by Route of Administration
13.2.5. Market Revenue and Forecast, by End-use
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapeutic Type
13.2.6.2. Market Revenue and Forecast, by Indication
13.2.6.3. Market Revenue and Forecast, by Mechanism of Action
13.2.7. Market Revenue and Forecast, by Route of Administration
13.2.8. Market Revenue and Forecast, by End-use
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapeutic Type
13.2.9.2. Market Revenue and Forecast, by Indication
13.2.9.3. Market Revenue and Forecast, by Mechanism of Action
13.2.10. Market Revenue and Forecast, by Route of Administration
13.2.11. Market Revenue and Forecast, by End-use
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapeutic Type
13.2.12.2. Market Revenue and Forecast, by Indication
13.2.12.3. Market Revenue and Forecast, by Mechanism of Action
13.2.12.4. Market Revenue and Forecast, by Route of Administration
13.2.13. Market Revenue and Forecast, by End-use
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapeutic Type
13.2.14.2. Market Revenue and Forecast, by Indication
13.2.14.3. Market Revenue and Forecast, by Mechanism of Action
13.2.14.4. Market Revenue and Forecast, by Route of Administration
13.2.15. Market Revenue and Forecast, by End-use
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapeutic Type
13.3.2. Market Revenue and Forecast, by Indication
13.3.3. Market Revenue and Forecast, by Mechanism of Action
13.3.4. Market Revenue and Forecast, by Route of Administration
13.3.5. Market Revenue and Forecast, by End-use
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapeutic Type
13.3.6.2. Market Revenue and Forecast, by Indication
13.3.6.3. Market Revenue and Forecast, by Mechanism of Action
13.3.6.4. Market Revenue and Forecast, by Route of Administration
13.3.7. Market Revenue and Forecast, by End-use
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapeutic Type
13.3.8.2. Market Revenue and Forecast, by Indication
13.3.8.3. Market Revenue and Forecast, by Mechanism of Action
13.3.8.4. Market Revenue and Forecast, by Route of Administration
13.3.9. Market Revenue and Forecast, by End-use
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapeutic Type
13.3.10.2. Market Revenue and Forecast, by Indication
13.3.10.3. Market Revenue and Forecast, by Mechanism of Action
13.3.10.4. Market Revenue and Forecast, by Route of Administration
13.3.10.5. Market Revenue and Forecast, by End-use
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapeutic Type
13.3.11.2. Market Revenue and Forecast, by Indication
13.3.11.3. Market Revenue and Forecast, by Mechanism of Action
13.3.11.4. Market Revenue and Forecast, by Route of Administration
13.3.11.5. Market Revenue and Forecast, by End-use
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapeutic Type
13.4.2. Market Revenue and Forecast, by Indication
13.4.3. Market Revenue and Forecast, by Mechanism of Action
13.4.4. Market Revenue and Forecast, by Route of Administration
13.4.5. Market Revenue and Forecast, by End-use
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapeutic Type
13.4.6.2. Market Revenue and Forecast, by Indication
13.4.6.3. Market Revenue and Forecast, by Mechanism of Action
13.4.6.4. Market Revenue and Forecast, by Route of Administration
13.4.7. Market Revenue and Forecast, by End-use
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapeutic Type
13.4.8.2. Market Revenue and Forecast, by Indication
13.4.8.3. Market Revenue and Forecast, by Mechanism of Action
13.4.8.4. Market Revenue and Forecast, by Route of Administration
13.4.9. Market Revenue and Forecast, by End-use
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapeutic Type
13.4.10.2. Market Revenue and Forecast, by Indication
13.4.10.3. Market Revenue and Forecast, by Mechanism of Action
13.4.10.4. Market Revenue and Forecast, by Route of Administration
13.4.10.5. Market Revenue and Forecast, by End-use
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapeutic Type
13.4.11.2. Market Revenue and Forecast, by Indication
13.4.11.3. Market Revenue and Forecast, by Mechanism of Action
13.4.11.4. Market Revenue and Forecast, by Route of Administration
13.4.11.5. Market Revenue and Forecast, by End-use
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapeutic Type
13.5.2. Market Revenue and Forecast, by Indication
13.5.3. Market Revenue and Forecast, by Mechanism of Action
13.5.4. Market Revenue and Forecast, by Route of Administration
13.5.5. Market Revenue and Forecast, by End-use
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapeutic Type
13.5.6.2. Market Revenue and Forecast, by Indication
13.5.6.3. Market Revenue and Forecast, by Mechanism of Action
13.5.6.4. Market Revenue and Forecast, by Route of Administration
13.5.7. Market Revenue and Forecast, by End-use
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapeutic Type
13.5.8.2. Market Revenue and Forecast, by Indication
13.5.8.3. Market Revenue and Forecast, by Mechanism of Action
13.5.8.4. Market Revenue and Forecast, by Route of Administration
13.5.8.5. Market Revenue and Forecast, by End-use
14.1. Biogen Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Eisai Co., Ltd.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. F. Hoffmann-La Roche Ltd.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Eli Lilly and Company
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Novartis AG
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Pfizer Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. AbbVie Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Johnson & Johnson
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. AC Immune SA
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Alzheon Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
